# TRANSCEND FL (NCT04245839)

> A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04245839
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celgene
- Conditions: Lymphoma, Non-Hodgkin
- Interventions: Fludarabine; Cyclophosphamide; JCAR017
- Enrollment: 276
- Primary outcome: Overall Response Rate (ORR)

## Commentary we found

- X threads: 16
- YouTube: 10
- Podcasts: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=transcend-fl-nct04245839

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04245839", "email": "<work email>"}; the inbox owner confirms by the emailed link.